Telotristat With Lutathera in Neuroendocrine Tumors
Study of Telotristat (Xermelo) in Combination With Luetetium Lu177 Dotatate (Lutathera) in Well-Differentiated Neuroendocrine Tumors
Sponsor: Lowell Anthony, MD
Terminated
Sponsor cancelled research
Other terminated trials from Lowell Anthony, MD
More terminations from Lowell Anthony, MD
Listed as NCT04543955, this PHASE2 trial focuses on Neuroendocrine Tumors and remains terminated or withdrawn. Sponsored by Lowell Anthony, MD, it has been updated 9 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2023 — Jul 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Nov 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Nov 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lowell Anthony, MD
- TerSera Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .